drug price – Page 2

Novartis and Boehringer Ingelheim Launch Direct-to-Consumer Drug Sales, Bypassing Middlemen

1 month ago talkbio0Tagged Boehringer Ingelheim, Cosentyx, Direct-to-Consumer, drug price, DTC, middlemen, Novartis, Patient access, Pharmaceutical Sales, PhRMA, Spiriva Respimat

Boehringer Ingelheim; Novartis; Direct-to-consumer (DTC); Pharmaceutical sales; Middlemen; Drug pricing; Patient access; Cosentyx; Spiriva Respimat; PhRMA

White House ‘Most Favored Nation’ Deadline Drives Pharma Concessions Amid Threats of Enforcement

1 month ago talkbio0Tagged deadline, drug manufacturers, drug price, Medicaid, Medicare, Nation, Pharma Concessions, pharmaceutical companies, prescription drug costs, Trump administration, White House

most favored nation; drug pricing; White House; executive order; pharmaceutical companies; Medicaid; Medicare; drug manufacturers; Trump administration; prescription drug costs; deadline; pharma concessions

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

1 month ago talkbio0Tagged Commitment Deadline, direct-to-consumer sales, drug price, executive order, international reference price, Medicaid, MFN, Most-Favored-Nation, Parity, pharmaceutical manufacturers, Prices, Pricing, tariffs, Transplant Registry Unified Management Program

Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price

AstraZeneca Appeals to Supreme Court in Final Attempt to Challenge Medicare Drug Price Negotiation Program

1 month ago talkbio0Tagged AstraZeneca, drug price, Farxiga, Inflation Reduction Act, Medicare, Myasthenic Syndromes, Congenital, Negotiation Program, Supreme Court

AstraZeneca; Medicare Drug Price Negotiation Program; Supreme Court; Inflation Reduction Act; Third Circuit; due process; pharmaceuticals; CMS; drug pricing; Farxiga

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

1 month ago talkbio0Tagged Antipsychotic Agents, Cholinergic Receptors, Cobenfy, drug price, launch, Myers, Nance-Horan syndrome, Prices, Schizophrenia, squibb, U.S., UK

Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026

A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences

2 months ago talkbio0Tagged AstraZeneca, Biological Science Disciplines, drug price, drug spending, eli lilly, Government, Investments, Merck, Nance-Horan syndrome, pharmaceutical divestment, Policy, R&D, sanofi, UK

UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending

Eli Lilly Loses Appeal to Overturn $183.7 Million Medicaid Rebate Judgment

2 months ago talkbio0Tagged appeal, Circuit, court, drug price, eli lilly, False Claims Act, Fraud, judgment, Medicaid, Positive

Eli Lilly; Medicaid; rebate; court ruling; False Claims Act; drug pricing; whistleblower; 7th Circuit Court of Appeals; fraud; $183.7 million judgment

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

2 months ago talkbio0Tagged adaptation, Apis (invertebrate), Clinical Trials, drug price, Generalized, Investments, manufacturing uncertainty, Market, Pharma, Policy, regulatory environment, Reinvention, resilience, strategic reserves, supply chain

pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves